請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60674
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學 | |
dc.contributor.author | Pee-Fang Lai | en |
dc.contributor.author | 賴碧芳 | zh_TW |
dc.date.accessioned | 2021-06-16T10:25:37Z | - |
dc.date.available | 2018-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-15 | |
dc.identifier.citation | 1. Siegel, R., Naishadham, D. and Jemal, A. (2013) Cancer statistics, 2013. CA: a cancer journal for clinicians, 63, 11-30.
2. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J. and Thun, M.J. (2005) Cancer statistics, 2005. CA: a cancer journal for clinicians, 55, 10-30. 3. De Marzo, A.M., DeWeese, T.L., Platz, E.A., Meeker, A.K., Nakayama, M., Epstein, J.I., Isaacs, W.B. and Nelson, W.G. (2004) Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. Journal of cellular biochemistry, 91, 459-477. 4. Huggins, C. (1967) Endocrine-induced regression of cancers. Cancer Res, 27, 1925-1930. 5. Palmberg, C., Koivisto, P., Visakorpi, T. and Tammela, T.L. (1999) PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol, 36, 191-196. 6. Denmeade, S.R. and Isaacs, J.T. (2002) A history of prostate cancer treatment. Nature reviews. Cancer, 2, 389-396. 7. Coussens, L.M. and Werb, Z. (2002) Inflammation and cancer. Nature, 420, 860-867. 8. Ames, B.N., Gold, L.S. and Willett, W.C. (1995) The causes and prevention of cancer. Proceedings of the National Academy of Sciences of the United States of America, 92, 5258-5265. 9. Cerutti, P.A. and Trump, B.F. (1991) Inflammation and oxidative stress in carcinogenesis. Cancer cells, 3, 1-7. 10. Hussain, S.P., Hofseth, L.J. and Harris, C.C. (2003) Radical causes of cancer. Nature reviews. Cancer, 3, 276-285. 11. Nelson, W.G., De Marzo, A.M., DeWeese, T.L. and Isaacs, W.B. (2004) The role of inflammation in the pathogenesis of prostate cancer. The Journal of urology, 172, S6-11; discussion S11-12. 12. Goldstraw, M.A., Fitzpatrick, J.M. and Kirby, R.S. (2007) What is the role of inflammation in the pathogenesis of prostate cancer? BJU international, 99, 966-968. 13. Engl, T., Relja, B., Blumenberg, C., Muller, I., Ringel, E.M., Beecken, W.D., Jonas, D. and Blaheta, R.A. (2006) Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life sciences, 78, 1784-1793. 14. Nakai, Y. and Nonomura, N. (2013) Inflammation and prostate carcinogenesis. International journal of urology : official journal of the Japanese Urological Association, 20, 150-160. 15. De Marzo, A.M., Marchi, V.L., Epstein, J.I. and Nelson, W.G. (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol, 155, 1985-1992. 16. Simmons, D.L., Botting, R.M. and Hla, T. (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological reviews, 56, 387-437. 17. Hata, A.N. and Breyer, R.M. (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacology & therapeutics, 103, 147-166. 18. Gupta, R.A. and Dubois, R.N. (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature reviews. Cancer, 1, 11-21. 19. Kirschenbaum, A., Klausner, A.P., Lee, R., Unger, P., Yao, S., Liu, X.H. and Levine, A.C. (2000) Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56, 671-676. 20. Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., Kobayashi, M., Satoh, K., Narita, M., Sugimoto, Y. et al. (2003) Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. The Journal of experimental medicine, 197, 221-232. 21. Dempke, W., Rie, C., Grothey, A. and Schmoll, H.J. (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? Journal of cancer research and clinical oncology, 127, 411-417. 22. Wang, D. and Dubois, R.N. (2006) Prostaglandins and cancer. Gut, 55, 115-122. 23. Sugimoto, Y. and Narumiya, S. (2007) Prostaglandin E receptors. The Journal of biological chemistry, 282, 11613-11617. 24. Fulton, A.M., Ma, X. and Kundu, N. (2006) Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer research, 66, 9794-9797. 25. Legler, D.F., Bruckner, M., Uetz-von Allmen, E. and Krause, P. (2010) Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol, 42, 198-201. 26. Ansari, K.M., Rundhaug, J.E. and Fischer, S.M. (2008) Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Molecular cancer research : MCR, 6, 1003-1016. 27. Poligone, B. and Baldwin, A.S. (2001) Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. The Journal of biological chemistry, 276, 38658-38664. 28. Buchanan, F.G., Wang, D., Bargiacchi, F. and DuBois, R.N. (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. The Journal of biological chemistry, 278, 35451-35457. 29. Majima, M., Amano, H. and Hayashi, I. (2003) Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends in pharmacological sciences, 24, 524-529. 30. O'Neill, G.P. and Ford-Hutchinson, A.W. (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS letters, 330, 156-160. 31. Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D.G. and Mukhtar, H. (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. The Prostate, 42, 73-78. 32. Half, E., Tang, X.M., Gwyn, K., Sahin, A., Wathen, K. and Sinicrope, F.A. (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer research, 62, 1676-1681. 33. Lee, L.M., Pan, C.C., Cheng, C.J., Chi, C.W. and Liu, T.Y. (2001) Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer research, 21, 1291-1294. 34. Kulmacz, R.J., van der Donk, W.A. and Tsai, A.L. (2003) Comparison of the properties of prostaglandin H synthase-1 and -2. Progress in lipid research, 42, 377-404. 35. Platz, E.A., Rohrmann, S., Pearson, J.D., Corrada, M.M., Watson, D.J., De Marzo, A.M., Landis, P.K., Metter, E.J. and Carter, H.B. (2005) Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev, 14, 390-396. 36. Guadagni, F., Ferroni, P., Palmirotta, R., Del Monte, G., Formica, V. and Roselli, M. (2007) Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res, 27, 3147-3162. 37. Chang, S.H., Liu, C.H., Conway, R., Han, D.K., Nithipatikom, K., Trifan, O.C., Lane, T.F. and Hla, T. (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 101, 591-596. 38. Grosch, S., Maier, T.J., Schiffmann, S. and Geisslinger, G. (2006) Cyclooxygenase-2 (COX-2)-Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. JNCI Journal of the National Cancer Institute, 98, 736-747. 39. Yang, C.Y., Meng, C.L., Liao, C.L. and Wong, P.Y. (2003) Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines. Prostaglandins & other lipid mediators, 72, 115-130. 40. Gupta, S., Adhami, V.M., Subbarayan, M., MacLennan, G.T., Lewin, J.S., Hafeli, U.O., Fu, P. and Mukhtar, H. (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer research, 64, 3334-3343. 41. Koehne, C.H. and Dubois, R.N. (2004) COX-2 inhibition and colorectal cancer. Seminars in oncology, 31, 12-21. 42. Chun, K.S. and Surh, Y.J. (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochemical pharmacology, 68, 1089-1100. 43. Moorghen, M., Ince, P., Finney, K.J., Sunter, J.P., Appleton, D.R. and Watson, A.J. (1988) A protective effect of sulindac against chemically-induced primary colonic tumours in mice. The Journal of pathology, 156, 341-347. 44. Taylor, M.T., Lawson, K.R., Ignatenko, N.A., Marek, S.E., Stringer, D.E., Skovan, B.A. and Gerner, E.W. (2000) Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer research, 60, 6607-6610. 45. Herrmann, C., Block, C., Geisen, C., Haas, K., Weber, C., Winde, G., Moroy, T. and Muller, O. (1998) Sulindac sulfide inhibits Ras signaling. Oncogene, 17, 1769-1776. 46. Lim, J.T., Piazza, G.A., Han, E.K., Delohery, T.M., Li, H., Finn, T.S., Buttyan, R., Yamamoto, H., Sperl, G.J., Brendel, K. et al. (1999) Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochemical pharmacology, 58, 1097-1107. 47. Tinsley, H.N., Gary, B.D., Keeton, A.B., Zhang, W., Abadi, A.H., Reynolds, R.C. and Piazza, G.A. (2009) Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Molecular cancer therapeutics, 8, 3331-3340. 48. Piazza, G.A., Rahm, A.L., Krutzsch, M., Sperl, G., Paranka, N.S., Gross, P.H., Brendel, K., Burt, R.W., Alberts, D.S., Pamukcu, R. et al. (1995) Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer research, 55, 3110-3116. 49. Han, E.K., Arber, N., Yamamoto, H., Lim, J.T., Delohery, T., Pamukcu, R., Piazza, G.A., Xing, W.Q. and Weinstein, I.B. (1998) Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast cancer research and treatment, 48, 195-203. 50. Thompson, H.J., Jiang, C., Lu, J., Mehta, R.G., Piazza, G.A., Paranka, N.S., Pamukcu, R. and Ahnen, D.J. (1997) Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer research, 57, 267-271. 51. Shi, Y.E., Torri, J., Yieh, L., Wellstein, A., Lippman, M.E. and Dickson, R.B. (1993) Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer research, 53, 1409-1415. 52. Oberst, M.D., Williams, C.A., Dickson, R.B., Johnson, M.D. and Lin, C.Y. (2003) The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. The Journal of biological chemistry, 278, 26773-26779. 53. Lee, M.S., Kiyomiya, K., Benaud, C., Dickson, R.B. and Lin, C.Y. (2005) Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. American journal of physiology. Cell physiology, 288, C932-941. 54. Benaud, C., Oberst, M., Hobson, J.P., Spiegel, S., Dickson, R.B. and Lin, C.Y. (2002) Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. The Journal of biological chemistry, 277, 10539-10546. 55. Kiyomiya, K., Lee, M.S., Tseng, I.C., Zuo, H., Barndt, R.J., Johnson, M.D., Dickson, R.B. and Lin, C.Y. (2006) Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. American journal of physiology. Cell physiology, 291, C40-49. 56. Lee, M.S., Tseng, I.C., Wang, Y., Kiyomiya, K., Johnson, M.D., Dickson, R.B. and Lin, C.Y. (2007) Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. American journal of physiology. Cell physiology, 293, C95-105. 57. Cho, E.G., Schwartz, R.H. and Kim, M.G. (2005) Shedding of membrane epithin is blocked without LDLRA4 and its protease activation site. Biochemical and biophysical research communications, 327, 328-334. 58. Kim C, C.Y., Kang CH, Kim MG, Lee H, Cho EG, Park D. (2005) Filamin is essential for shedding of the transmembrane serine protease, epithin. EMBO Rep., 6, 1045-1051. 59. Oberst, M.D., Chen, L.Y., Kiyomiya, K., Williams, C.A., Lee, M.S., Johnson, M.D., Dickson, R.B. and Lin, C.Y. (2005) HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. American journal of physiology, 289, C462-470. 60. Benaud, C., Dickson, R.B. and Lin, C.Y. (2001) Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. European journal of biochemistry / FEBS, 268, 1439-1447. 61. Takeuchi, T., Harris, J.L., Huang, W., Yan, K.W., Coughlin, S.R. and Craik, C.S. (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. The Journal of biological chemistry, 275, 26333-26342. 62. Lee, S.L., Dickson, R.B. and Lin, C.Y. (2000) Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. The Journal of biological chemistry, 275, 36720-36725. 63. Jin, X., Yagi, M., Akiyama, N., Hirosaki, T., Higashi, S., Lin, C.Y., Dickson, R.B., Kitamura, H. and Miyazaki, K. (2006) Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer science, 97, 1327-1334. 64. Ahmed, S., Jin, X., Yagi, M., Yasuda, C., Sato, Y., Higashi, S., Lin, C.Y., Dickson, R.B. and Miyazaki, K. (2006) Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). The FEBS journal, 273, 615-627. 65. Lin, C.Y., Anders, J., Johnson, M. and Dickson, R.B. (1999) Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem, 274, 18237-18242. 66. Lin, C.Y., Anders, J., Johnson, M., Sang, Q.A. and Dickson, R.B. (1999) Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem, 274, 18231-18236. 67. Saleem, M., Adhami, V.M., Zhong, W., Longley, B.J., Lin, C.Y., Dickson, R.B., Reagan-Shaw, S., Jarrard, D.F. and Mukhtar, H. (2006) A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 15, 217-227. 68. Ding, K.F., Sun, L.F., Ge, W.T., Hu, H.G., Zhang, S.Z. and Zheng, S. (2005) Effect of SNC19/ST14 gene overexpression on invasion of colorectal cancer cells. World J Gastroenterol, 11, 5651-5654. 69. Friis, S., Uzzun Sales, K., Godiksen, S., Peters, D.E., Lin, C.Y., Vogel, L.K. and Bugge, T.H. (2013) A Matriptase-Prostasin Reciprocal Zymogen Activation Complex with Unique Features: PROSTASIN AS A NON-ENZYMATIC CO-FACTOR FOR MATRIPTASE ACTIVATION. The Journal of biological chemistry, 288, 19028-19039. 70. Galkin, A.V., Mullen, L., Fox, W.D., Brown, J., Duncan, D., Moreno, O., Madison, E.L. and Agus, D.B. (2004) CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. The Prostate, 61, 228-235. 71. Eberhart, C.E., Coffey, R.J., Radhika, A., Giardiello, F.M., Ferrenbach, S. and DuBois, R.N. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-1188. 72. Liu, C.H., Chang, S.H., Narko, K., Trifan, O.C., Wu, M.T., Smith, E., Haudenschild, C., Lane, T.F. and Hla, T. (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. The Journal of biological chemistry, 276, 18563-18569. 73. Tai, H., Miyaura, C., Pilbeam, C.C., Tamura, T., Ohsugi, Y., Koishihara, Y., Kubodera, N., Kawaguchi, H., Raisz, L.G. and Suda, T. (1997) Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology, 138, 2372-2379. 74. Welman, A., Sproul, D., Mullen, P., Muir, M., Kinnaird, A.R., Harrison, D.J., Faratian, D., Brunton, V.G. and Frame, M.C. (2012) Diversity of matriptase expression level and function in breast cancer. PloS one, 7, e34182. 75. Tjandrawinata, R.R. and Hughes-Fulford, M. (1997) Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. Advances in experimental medicine and biology, 407, 163-170. 76. Gregor, J.I., Kilian, M., Heukamp, I., Kiewert, C., Kristiansen, G., Schimke, I., Walz, M.K., Jacobi, C.A. and Wenger, F.A. (2005) Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. Prostaglandins, leukotrienes, and essential fatty acids, 73, 89-97. 77. Munoz-Espada, A.C. and Watkins, B.A. (2006) Cyanidin attenuates PGE2 production and cyclooxygenase-2 expression in LNCaP human prostate cancer cells. The Journal of nutritional biochemistry, 17, 589-596. 78. Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J.M., Evans, J.F. and Taketo, M.M. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809. 79. Kang, Y.J., Mbonye, U.R., DeLong, C.J., Wada, M. and Smith, W.L. (2007) Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Progress in lipid research, 46, 108-125. 80. List, K., Szabo, R., Molinolo, A., Sriuranpong, V., Redeye, V., Murdock, T., Burke, B., Nielsen, B.S., Gutkind, J.S. and Bugge, T.H. (2005) Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes & development, 19, 1934-1950. 81. Wu, S.R., Cheng, T.S., Chen, W.C., Shyu, H.Y., Ko, C.J., Huang, H.P., Teng, C.H., Lin, C.H., Johnson, M.D., Lin, C.Y. et al. (2010) Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. The American journal of pathology, 177, 3145-3158. 82. Narumiya, S., Sugimoto, Y. and Ushikubi, F. (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev, 79, 1193-1226. 83. Wang, X. and Klein, R.D. (2007) Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Molecular Carcinogenesis, 46, 912-923. 84. Srinath, P., Rao, P.N., Knaus, E.E. and Suresh, M.R. (2003) Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer research, 23, 3923-3928. 85. Kulp, S.K., Yang, Y.T., Hung, C.C., Chen, K.F., Lai, J.P., Tseng, P.H., Fowble, J.W., Ward, P.J. and Chen, C.S. (2004) 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer research, 64, 1444-1451. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60674 | - |
dc.description.abstract | 近年來在台灣,攝護腺癌的發生率以及死亡率有逐年增加的趨勢。有些研究指出慢性發炎與攝護腺癌的早期發生以及惡化有關。亞型環氧化酶 (Cyclooxygenase-2, COX-2) 是一種花生四烯酸 (arachidonic acid, AA) 代謝過程中合成前列腺素 (prostaglandins, PGs) 的限速酶,近年研究指出亞型環氧化酶在一些癌症,如大腸癌,乳癌,肺癌以及攝護腺癌具有高度表達的現象。然而,亞型環氧化酶是否參與攝護腺癌細胞侵襲的分子機制尚未了解。在本篇研究裡,我建立了在攝護腺癌細胞PC-3高度表現亞型環氧化酶以及抑制亞型環氧化酶表現量的細胞模式,進而探討攝護腺癌細胞的侵襲能力。結果發現大量表現亞型環氧化酶增加了攝護腺癌細胞PC-3的侵襲能力以及第二型嵌膜絲胺酸蛋白酶間質蛋白酶(Matriptase)的活化。相反地,抑制亞型環氧化酶的表現量亦降低了攝護腺癌細胞的侵襲能力,同時抑制了間質蛋白酶的活化程度。為了更進一步研究亞型環氧化酶在攝護腺癌細胞中扮演的角色,我發現亞型環氧化酶的主要產物前列腺素E2 (PGE2) 可促進攝護腺癌細胞的侵襲能力及刺激間質蛋白酶的活化。實驗結果指出PGE2刺激間質蛋白酶活化的分子機制可能是透過AKT訊息傳遞。另外,本篇實驗結果也指出,在一些抑制亞型環氧化酶及非類固醇抗炎藥物 (NSAIDs) 中,希樂葆 (Celebrex) 和硫化舒磷酸 (Sulindac Sulfide) 可有效地抑制攝護腺癌細胞的移動與侵襲能力以及降低間質蛋白酶的活化。整體來說,亞型環氧化酶的表現量可能藉由影響間質蛋白酶的活化來調控攝護腺癌細胞的侵襲能力。因此探討亞型環氧化酶是未來一個具有潛力的課題,藉由抑制此酵素也許是一個有效的策略,進而降低攝護腺癌的惡化。 | zh_TW |
dc.description.abstract | The recent incidence of prostate cancer (PCa) is annually rising in Taiwan. Chronic inflammation has been revealed to contribute to the early development and progression of PCa. Several studies have indicated that cyclooxygenase-2 (COX-2), a key enzyme to generate prostaglandins during inflammation is commonly overexpressed in human cancers including PCa, and correlated with PCa progression. However, the molecular mechanism how COX-2 promotes PCa cell invasion is not well understood. In this study, we investigated the role of COX-2 in PCa cell invasion and delineated the molecular mechanism in which COX-2 signaling involved in PCa cell invasion. Using overexpression and knockdown approaches. the results showed that COX-2 overexpression could enhance PCa PC3 cell invasion, partly due to up-regulating matriptase, while COX-2 knockdown resulted in decreasing the cancer cell invasion, and the activated level of matriptase. Moreover, PGE2, the major prostaglandin of COX-2, was able to induce PCa cell invasion and matriptase activation. With NSAIDs, the data showed that sulindac sulfide and celebrex exhibited significant effects on suppressing PCa cell invasion and down-regulating matriptase. Taken together, the data indicate that COX-2 is involved in promoting PCa cell invasion, at least in part due to increasing matriptase activation, suggesting that suppression of COX-2 signaling may be a strategy to reduce PCa progression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T10:25:37Z (GMT). No. of bitstreams: 1 ntu-102-R00442031-1.pdf: 4437547 bytes, checksum: 102e93b508ac1292b0720e1d354e9303 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract iii Chapter 1. Introduction 1 1.1 Prostate cancer 2 1.2 Inflammation and prostate carcinogenesis 2 1.3 Cyclooxygenase-2 (COX-2) 3 1.4 COX-2 and prostate cancer 5 1.5 Non-steroidal anti-inflammatory drugs (NSAIDs) 6 1.6 Matriptase 8 1.7 Research motivation and purpose 11 Chapter 2. Materials and Methods 12 2.1 Materials 13 2.2 Methods 17 2.3 Buffers 26 Chapter 3. Results 28 3.1 Part 1: Roles of COX-2 in prostate cancer. 3.1.1 COX-2 was involved in regulation of matriptase activation and prostate cancer PC-3 and LNCaP cell invasion 29 3.1.2 Effects of COX-2 silencing in matriptase activation and expression in Pc-3 cells 30 3.1.3 Effects of COX-2 knockdown on PC-3 cell invasion and migration 31 3.1.4 Prostaglandin E2 (PGE2) induced prostate cancer cell invasion in PC-3 cells 31 3.1.5 PGE2 increased the activated levels of matriptase in PC-3 cells. 32 3.1.6 PGE2 induced PI3K/AKT or Erk1/2 activity in PC-3 cells 32 3.1.7 PGE2 increased prostate cancer LNCaP cell invasion 33 3.1.8 Expression levels of EP receptors in prostate cancer cells 34 3.2 Part 2: Effects of different COX-2 inhibitors on the matriptase and cell invasion of prostate cancer 3.2.1 Effects of NSAIDs on matriptase and HAI-1 in PC-3 cells 35 3.2.2 Effects of NSAIDs (Celebrex, Sulindac sulfide, Sulindac sulfone) on the viability of PC-3 cells 35 3.2.3 Effects of celebrex on decreasing the activated levels of matriptase. 36 3.2.4 Inhibitory effects of sulindac sulfide on PC-3 cell invasion and migration via suppressing the total and activated levels of matriptase. 36 3.2.5 Effects of sulindac sulfone on the total and activated levels of matriptase in PC-3 cells. 37 3.2.6 Inhibitory effects of celebrex and sulindac sulfide on LNCaP cell invasion. 37 Chapter 4. Discussion 39 Chapter 5. Figures 44 Chapter 6. References 70 LIST OF FIGURES Figure 1. Establishment of COX-2-overexpressing PC3 and LNCaP cells, and analysis of the COX-2 overexpression effects on matriptase and both cancer cell invasion. 47 Figure 2. Examination of COX-2 knockdown effects on matriptase, HAI-1, and mRNA expression levels in PC-3 cells. 50 Figure 3. Analysis of the invasion of COX-2 knockdown PC-3 cells. 52 Figure 4. Effects of PGE2 on PC3 cell invasion. 53 Figure 5. Dose-dependent and time-kinetic effects of PGE2 on the total and activated levels of matriptase in PC-3 cells. 55 Figure 6. Time-kinetic effect of PGE2 on the phosphorylation levels of Akt and Erks, as well as COX-2 expression in PC-3 cells. 58 Figure 7. Effect of PGE2 on prostate cancer LNCaP cell invasion. 59 Figure 8. Expression of EP receptors on prostate cancer PC-3, LNCap, and PNT2 cells. 60 Figure 9. Effect of NSAIDs on matriptase and HAI-1 in PC-3 cells. 61 Figure 10. Effects of Celebrex, Sulindac Sulfide, and Sulindac Sulfone on the cell viability of PC-3 cells.. 63 Figure 11. Effect of celebrex on the total and activated levels of matriptase in PC-3 cells in the presence or absence of FBS. 64 Figure 12. Effect of sulindac sulfide on PC-3 cell migration, invasion and the protein levels of matriptase. 66 Figure 13. Effects of sulindac sulfone on the total and activated levels of matriptase in PC-3 cells. 67 Figure 14. Effects of celebrex and sulindac Sulfide on the cell viability of LNCaP, and cell invasion in LNCap cells. 68 | |
dc.language.iso | en | |
dc.title | 探討亞型環氧化酶在攝護腺癌細胞的侵襲以及間質蛋白酶活化的影響 | zh_TW |
dc.title | Role of Cyclooxygenase-2 in prostate cancer cell invasion and modulating matriptase activity. | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 符文美,呂紹俊,余明俊 | |
dc.subject.keyword | 攝護腺癌,亞型環氧化?第二型嵌膜絲胺酸蛋白?前列腺素, | zh_TW |
dc.subject.keyword | prostate cancer,cyclooxygenase-2,matriptase,PGE2, | en |
dc.relation.page | 77 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 4.33 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。